Drug Insights

Your Ultimate Guide to Finding Glutathione on Synapse

22 March 2024
2 min read

Glutathione, a diminutive molecule drug, is a versatile medication used to treat a diverse range of medical conditions, such as cataracts, corneal ulcers, keratitis, chemotherapy-induced poisoning, and liver diseases. Despite its extensive utilization, its target and mechanism of action remain shrouded in mystery. Interestingly, the originator organization responsible for its approval in October 1966 is also unknown, adding to the enigma surrounding this medication. Although little is known about its mechanisms, it is believed to be a potent antioxidant that shields cells from oxidative damage. The route of administration, either intravenously or topically, depends on the medical condition under treatment. In summary, glutathione remains a riddle that has proven beneficial in treating an array of ailments, but its complete mechanism and targets warrant further investigation. Click on the image below to begin the exploration journey of Glutathione through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Brenig Therapeutics Presents New LRRK2 Inhibitor Findings for Parkinson's Disease at 2024 ACS Spring Meeting
Latest Hotspot
3 min read
Brenig Therapeutics Presents New LRRK2 Inhibitor Findings for Parkinson's Disease at 2024 ACS Spring Meeting
22 March 2024
During the 2024 ACS Spring Meeting, Brenig Therapeutics showcased novel findings related to their leading LRRK2 inhibitor, which is aimed at tackling Parkinson's disease.
Read →
Eli Lilly Reveals the Crystal Form Patent of FGFR3, Unveiling the Structure of LOXO-435
Hot Spotlight
6 min read
Eli Lilly Reveals the Crystal Form Patent of FGFR3, Unveiling the Structure of LOXO-435
21 March 2024
On March 14, 2024, Eli Lilly unveiled a WO patent for a crystalline salt form of an FGFR3 inhibitor, likely relating to LOXO-435's structure, within the pyrimido[4,5-b]pyrazine compound class.
Read →
GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (5)
GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (5)
21 March 2024
In this article, we will focus on Sosei Heptares, a leading company in the field of GPCR new drug development, and its GPCR research and development pipeline.
Read →
Explore Ezetimibe on Synapse: Tips and Tricks for Better Search Results
Drug Insights
2 min read
Explore Ezetimibe on Synapse: Tips and Tricks for Better Search Results
21 March 2024
Ezetimibe, an enigmatic small molecule drug, bewilders the medical community with its ability to inhibit the NPC1L1 protein.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.